Skip to main content
SpringerLink
Log in

Update on Aspirin-Exacerbated Respiratory Disease

  • Anaphylaxis and Drug Allergy (DA Khan and M Castells, Section Editors)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Aspirin-exacerbated respiratory disease (AERD) is an acquired disease characterized by chronic eosinophilic airway inflammation with underlying dysregulation of arachidonic acid metabolism. The purpose of this paper is to review the latest developments in our understanding of the underlying pathophysiology including the role of eosinophils, mast cells, innate lymphoid cells (ILC2), and platelets. Clinical features such as respiratory reactions induced by alcohol, aggressive nasal polyposis, and anosmia will allow for earlier recognition of these patients in clinical practice. The current state of the art management of AERD will be addressed including the ongoing central role for aspirin desensitization and high-dose aspirin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Widal MF, Abramin P, Lermeyez J. Anaphylaxieet idosyncrasie. Presse Med. 1922;30:189–92.

    CAS  Google Scholar 

  2. Stevenson DD, Pleskow WW, Simon RA, Mathison DA, Lumry WR, Schatz M, et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol. 1984;73(4):500–7.

    Article  CAS  PubMed  Google Scholar 

  3. • Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180–6. Excellent look at long term outcomes of aspirin desensitiztion.

    Article  CAS  PubMed  Google Scholar 

  4. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118(4):773–86. quiz 87-8.

    Article  CAS  PubMed  Google Scholar 

  5. • Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–81. e1. Most comprehensive look at prevalence of AERD.

  6. Fan Y, Feng S, Xia W, Qu L, Li X, Chen S, et al. Aspirin-exacerbated respiratory disease in China: a cohort investigation and literature review. Am J Rhinol Allergy. 2012;26(1):e20–2.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G, DeRuyck N, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol. 2008;122(5):961–8.

    Article  CAS  PubMed  Google Scholar 

  8. Cardet JC, White AA, Barrett NA, Feldweg AM, Wickner PG, Savage J, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2014;2(2):208–13.

    Article  PubMed  PubMed Central  Google Scholar 

  9. White AA, Bosso JV, Stevenson DD. The clinical dilemma of “silent desensitization” in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2013;34(4):378–82.

    Article  CAS  PubMed  Google Scholar 

  10. Lee-Sarwar K, Johns C, Laidlaw TM, Cahill KN. Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(3):449–51.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Swierczynska-Krepa M, Sanak M, Bochenek G, Strek P, Cmiel A, Gielicz A, et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol. 2014;134(4):883–90.

    Article  CAS  PubMed  Google Scholar 

  12. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1608–14.

    Article  CAS  PubMed  Google Scholar 

  13. Steinke JW, Bradley D, Arango P, Crouse CD, Frierson H, Kountakis SE, et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol. 2003;111(2):342–9.

    Article  CAS  PubMed  Google Scholar 

  14. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 1998;101(4):834–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sampson AP, Cowburn AS, Sladek K, Adamek L, Nizankowska E, Szczeklik A, et al. Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Arch Allergy Immunol. 1997;113(1-3):355–7.

    Article  CAS  PubMed  Google Scholar 

  16. Perez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol. 2005;115(6):1189–96.

    Article  CAS  PubMed  Google Scholar 

  17. Schmid M, Gode U, Schafer D, Wigand ME. Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. Acta Otolaryngol. 1999;119(2):277–80.

    Article  CAS  PubMed  Google Scholar 

  18. Steinke JW, Culp JA, Kropf E, Borish L. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol. 2009;124(4):724–30. e4.

    Article  CAS  PubMed  Google Scholar 

  19. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 2002;46(8):2201–6.

    Article  CAS  PubMed  Google Scholar 

  20. Steinke JW, Liu L, Huyett P, Negri J, Payne SC, Borish L. Prominent role of IFN-gamma in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2013;132(4):856–65. e1-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. •• Liu T, Garofalo D, Feng C, Lai J, Katz H, Laidlaw TM, et al. Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on T prostanoid receptors. J Immunol. 2015;194(11):5061–8. First mouse model of AERD, helping to define pathophysiology.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119(16):3790–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Liu T, Laidlaw TM, Katz HR, Boyce JA. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A. 2013;110(42):16987–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med. 2002;347(19):1493–9.

    Article  CAS  PubMed  Google Scholar 

  25. Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2010;126(4):738–44.

    Article  CAS  PubMed  Google Scholar 

  26. Katial RK, Martucci M, Burnett T, Faino A, Finkas L, Liu S, et al. Nonsteroidal anti-inflammatory-induced inhibition of signal transducer and activator of transcription 6 (STAT-6) phosphorylation in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;138(2):579–85.

    Article  CAS  PubMed  Google Scholar 

  27. •• Machado-Carvalho L, Martin M, Torres R, Gabasa M, Alobid I, Mullol J, et al. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1beta/IL-1 type I receptor/COX-2 pathway: vicious circle in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(1):99–107. e7. Excellent work discovering a potential mechanism for the key findings of low PGE2 levels in AERD.

  28. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha, 11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol. 2003;111(4):743–9.

    Article  CAS  PubMed  Google Scholar 

  29. Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(1):245–52.

    Article  CAS  PubMed  Google Scholar 

  30. Chang JE, Doherty TA, Baum R, Broide D. Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis. J Allergy Clin Immunol. 2014;133(3):899–901. e3.

    Article  CAS  PubMed  Google Scholar 

  31. •• Moretta L, Locatelli F. Innate lymphoid cells in normal and disease: an introductory overview. Immunol Lett. 2016;179:1. Good review of innate lymphoid cells as the innate immune system plays a key role in AERD.

    Article  CAS  PubMed  Google Scholar 

  32. Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1566–76. e5.

    Article  CAS  PubMed  Google Scholar 

  33. Liu T, Kanaoka Y, Barrett NA, Feng C, Garofalo D, Lai J, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J Immunol. 2015;195(8):3537–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Cahill KN, Raby BA, Zhou X, Guo F, Thibault D, Baccarelli A, et al. Impaired E prostanoid2 expression and resistance to prostaglandin E2 in nasal polyp fibroblasts from subjects with aspirin-exacerbated respiratory disease. Am J Respir Cell Mol Biol. 2016;54(1):34–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. •• Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease: mediators and mechanisms of a clinical disease. J Allergy Clin Immunol. 2016. Sucinct review of known pathophysiology in AERD.

  36. • Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2003;111(5):913–21. quiz 22. Seminal work in AERD.

  37. Bochenek G, Nizankowska-Mogilnicka E. Aspirin-exacerbated respiratory disease: clinical disease and diagnosis. Immunol Allergy Clin N Am. 2013;33(2):147–61.

    Article  Google Scholar 

  38. Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep. 2009;9(2):155–63.

    Article  CAS  PubMed  Google Scholar 

  39. Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100(5):420–5.

    Article  PubMed  Google Scholar 

  40. National Asthma E, Prevention P. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–138.

    Google Scholar 

  41. Peters AT, Spector S, Hsu J, Hamilos DL, Baroody FM, Chandra RK, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol. 2014;113(4):347–85.

    Article  PubMed  Google Scholar 

  42. Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(5):711–8.

    Article  PubMed  Google Scholar 

  43. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98(2):172–4.

    Article  CAS  PubMed  Google Scholar 

  44. White AA, Stevenson DD, Woessner KM, Simon RA. Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies. Allergy Asthma Proc. 2013;34(2):138–42.

    Article  CAS  PubMed  Google Scholar 

  45. Williams AN, Simon RA, Woessner KM, Stevenson DD. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol. 2007;120(2):273–7.

    Article  CAS  PubMed  Google Scholar 

  46. Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2009;123(2):406–10.

    Article  CAS  PubMed  Google Scholar 

  47. •• Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy, Asthma Immunol Res. 2011;3(1):3–10. Succinct review of how to diagnose and manage AERD.

    Article  CAS  Google Scholar 

  48. Shaker M, Lobb A, Jenkins P, O’Rourke D, Takemoto SK, Sheth S, et al. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2008;121(1):81–7.

    Article  CAS  PubMed  Google Scholar 

  49. Esmaeilzadeh H, Nabavi M, Aryan Z, Arshi S, Bemanian MH, Fallahpour M, et al. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a randomized double-blind placebo-controlled trial. Clin Immunol. 2015;160(2):349–57.

    Article  CAS  PubMed  Google Scholar 

  50. Havel M, Ertl L, Braunschweig F, Markmann S, Leunig A, Gamarra F, et al. Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol. 2013;270(2):571–8.

    Article  PubMed  Google Scholar 

  51. Cho KS, Soudry E, Psaltis AJ, Nadeau KC, McGhee SA, Nayak JV, et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151(4):575–81.

    Article  PubMed  Google Scholar 

  52. Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2003;90(3):338–41.

    Article  CAS  PubMed  Google Scholar 

  53. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2007;119(1):157–64.

    Article  CAS  PubMed  Google Scholar 

  54. Bobolea I, Barranco P, Fiandor A, Cabanas R, Quirce S. Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol. 2010;20(5):448–9.

    CAS  PubMed  Google Scholar 

  55. Bergmann KC, Zuberbier T, Church MK. Omalizumab in the treatment of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(3):459–60.

    Article  PubMed  Google Scholar 

  56. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–6. e1.

    Article  CAS  PubMed  Google Scholar 

  57. Hayashi H, Mitsui C, Nakatani E, Fukutomi Y, Kajiwara K, Watai K, et al. Omalizumab reduces cysteinyl leukotriene and 9alpha, 11beta-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1585–7. e4.

    Article  CAS  PubMed  Google Scholar 

  58. Mitchell JE, Skypala I. Aspirin and salicylate in respiratory disease. Rhinology. 2013;51(3):195–205.

    CAS  PubMed  Google Scholar 

  59. Sommer DD, Hoffbauer S, Au M, Sowerby LJ, Gupta MK, Nayan S. Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. Otolaryngol Head Neck Surg. 2015;152(1):42–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Allergy, Asthma, and Immunology Division, Scripps Clinic Medical Group, 3811 Valley Centre Drive, San Diego, CA, 92130, USA

    Katharine M. Woessner

Authors
  1. Katharine M. Woessner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katharine M. Woessner.

Ethics declarations

Conflict of Interest

Dr. Woessner declares no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Anaphylaxis and Drug Allergy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Woessner, K.M. Update on Aspirin-Exacerbated Respiratory Disease. Curr Allergy Asthma Rep 17, 2 (2017). https://doi.org/10.1007/s11882-017-0673-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-017-0673-6

Keywords

Search

Navigation